[1] Wang K, Wang N, Sun J, Fan Y, Chen L. Primary prostate lymphoma: A case report and literature review. Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419863217. doi: 10.1177/2058738419863217. [2] Taleb A, Ismaili N, Belbaraka R, Bensouda A, Elghissassi I, Elmesbahi O, Droz JP, Errihani H., Primary lymphoma of the prostate treated with rituximab-based chemotherapy: a case report and review of the literature. Cases J. 2009 Aug 11;2:8875. doi: 10.1186/1757-1626-0002-0000008875. [3] Hu S, Wang Y, Yang L, Yi L, Nian Y. Primary non-Hodgkin's lymphoma of the prostate with intractable hematuria: A case report and review of the literature. Oncol Lett. 2015 Mar;9(3):1187-1190. doi: 10.3892/ol.2014.2829. [4] D'souza MM, Jaimini A, Bansal A, Tripathi M, Sharma R, Mondal A, Tripathi RP. Indian J Radiol Imaging. 2013 Oct;23(4):354-65. doi: 10.4103/0971-3026.125626. [5] Al Tabaa Y, Bailly C, Kanoun S. FDG-PET/CT in Lymphoma: Where Do We Go Now? Cancers (Basel). 2021 Oct 18;13(20):5222. doi: 10.3390/cancers13205222. [6] Jadvar H. FDG PET in Prostate Cancer. PET Clin. 2009 Apr 1;4(2):155-61. doi: 10.1016/j.cpet.2009.05.002. [7] Han C, Zhu L, Liu X, Ma S, Liu Y, Wang X. Insights Imaging. 2021 Jun 16;12(1):79. doi: 10.1186/s13244-021-01024-3. [8] Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B. Malignant lymphoma involving the prostate: report of 62 cases. Cancer 1998 Aug 15;83(4):732-8. doi: 10.1002/(sici)1097-0142(19980815)83:43.0.co;2-t.